UNSPSC 51343403: Tilorone

This classification denotes an antiviral agent with the molecular formula C25H34N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O6W7VEW6KS, chemically known as 2,7-bis-deae-fluorenone but generally known as tilorone, which bears US NIH Compound Identifier 5475. European Medicines Agency schedules Tilorone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11057MIG. The term TILORONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25, No. 10 1971, List 11).

UNSPSC 51343403 Tilorone, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The four most recent solicitations under this code involve naloxone and drug deactivation systems, direct-to-manufacturer pharmacy prescriptions, medical and first aid supplies for fire rescue, and generic multi-source pharmaceuticals and OTC products — none of which are tilorone-specific or even antiviral medications. The code appears to be a misclassification in these opportunities, suggesting either tagging error by issuing bodies or that tilorone procurement is not occurring at meaningful scale in the state and local market right now.

The geographic spread of recent activity spans Florida (Seminole County), Texas (HHS Commission), and Minnesota (MMCAP cooperative purchasing serving multiple states including Oregon), with issuers ranging from county health departments to state health and human services commissions to municipal fire departments using cooperative purchasing vehicles. The representative opportunities include Seminole County's IFB for naloxone and drug deactivation systems (response deadline July 26, 2023), the City of Tampa's ITB for medical and first aid supplies (due March 13, 2026, estimated contract value $700,000.00 with SLBE set-aside), the Texas HHS Commission's RFI on direct-to-manufacturer prescriptions (deadline April 3, 2026), and Minnesota MMCAP's RFP for generic pharmaceuticals and OTC products (due March 26, 2026). The code shows no relevant recent activity for tilorone procurement itself.